Concepedia

Author

Stéphanie Blanchard

Singapore Science Park

Also Known As

S. Blanchard, Sheryl S. Blanchard, Stephanie Blanchard, Stephanie E. Blanchard, Stéphanie Blanchard, Stéphanie Blanchard

37

Publications

712

Citations

13

H-Index

43

Concepts

All Affiliations

Singapore Science ParkExperimental Drug Development CentreAgency for Science, Technology and ResearchUniversity of Colorado DenverNational University of Singapore
SB

About

Stéphanie Blanchard is an author at Singapore Science Park specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

14

603

2

Natural Sciences

4

4

312

3

Health Sciences

2

2

43

4

Biochemistry

1

1

65

5

Biomolecular Engineering

1

1

41

Stéphanie Blanchard

×

18

Publications

657

Citations

13

H-Index

YearCitations

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard,

Journal of Medicinal Chemistry

2011

194

Discovery of Kinase Spectrum Selective Macrocycle (16<i>E</i>)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer

Anthony D. William, Angeline C.-H. Lee, Kee Chuan Goh,

Journal of Medicinal Chemistry

2011

99

Fragment-Based Ligand Design of Novel Potent Inhibitors of Tankyrases

Andreas Larsson, Anna Jansson, Fui Mee Ng,

Journal of Medicinal Chemistry

2013

65

Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)

Anders Poulsen, Anthony D. William, Stéphanie Blanchard,

Journal of Computer-Aided Molecular Design

2012

41

Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)

Anders Poulsen, Anthony D. William, Stéphanie Blanchard,

Journal of Molecular Modeling

2012

37

First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.

Matthew Chau Hsien Ng, David S.P. Tan, Vivek Subbiah,

Journal of Clinical Oncology

2017

33

Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602

Anders Poulsen, Harish Nagaraj, Angeline Lee,

Journal of Chemical Information and Modeling

2014

29

N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: Design, synthesis, SAR studies, and in vivo antitumor activity

Haishan Wang, Niefang Yu, Hongyan Song,

Bioorganic & Medicinal Chemistry Letters

2009

29

Hetarynic synthesis and chemical transformation of dihydrodipyridopyrazines

Stéphanie Blanchard, Ivan Rodriguez, Catherine Kuehm‐Caubere,

Tetrahedron

2002

18

Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors

Stéphanie Blanchard, Anthony D. William, Angeline C.-H. Lee,

Bioorganic & Medicinal Chemistry Letters

2010

17

Page 1